Furthermore, the inhibition of Rad51 promoted the resensitization of these previously resistant cells to anti-cancer therapy [99–101], which suggests that enhanced DNA repair activity in CSCs promotes their ability to overcome any double strand breaks during therapy. The gene discussed is RAD51; the disease is cancer.